Brentuximab vedotin: clinical updates and practical guidance

Jun Ho Yi; Seok Jin Kim; Won Seog Kim

doi:10.5045/br.2017.52.4.243

Quick links

Most Cited Most Read Ahead of Print Archives Go to E-submission

Review Article

Split Viewer

Blood Res 2017; 52(4):

Published online December 31, 2017

https://doi.org/10.5045/br.2017.52.4.243

Brentuximab vedotin: clinical updates and practical guidance

Jun Ho Yi¹, Seok Jin Kim², and Won Seog Kim^2*

Author Info. +

¹Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.

²Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Correspondence to : Won Seog Kim, M.D., Ph.D. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. wskimsmc@skku.edu

Received: May 10, 2017; Revised: November 30, 2017; Accepted: December 1, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Go to

Abstract

Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Administration. Thereafter, many large-scale trials in various situations have been performed, which led to extensions of the original indication. The aim of this review was to describe the latest updates on clinical trials of BV and the in-practice guidance for the use of BV.

Keywords Brentuximab vedotin, CD30, Antibody-drug conjugate, Hodgkin's lymphoma, Anaplastic large cell lymphoma

Article

Review Article

Blood Res 2017; 52(4): 243-253

Published online December 31, 2017 https://doi.org/10.5045/br.2017.52.4.243

Brentuximab vedotin: clinical updates and practical guidance

Jun Ho Yi¹, Seok Jin Kim², and Won Seog Kim^2*

¹Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.

²Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Correspondence to:Won Seog Kim, M.D., Ph.D. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. wskimsmc@skku.edu

Received: May 10, 2017; Revised: November 30, 2017; Accepted: December 1, 2017

Abstract

Keywords: Brentuximab vedotin, CD30, Antibody-drug conjugate, Hodgkin's lymphoma, Anaplastic large cell lymphoma

Abstract

Table 1 Real-world data of BV monotherapy in patients with relapsed or refractory Hodgkin's lymphoma compared with the pivotal study.

Abbreviations: CR, complete response; ORR, overall response rate; PFS, progression-free survival; SCT, stem cell transplantation (either autologous and/or allogeneic)..

Table 2 Results of BV-based combinations in patients with relapsed or refractory Hodgkin's lymphoma.

Abbreviations: CIR, central independent review; CR, complete response; INV, investigator; ORR, overall response rate..

Table 3 Real-world data for BV monotherapy in patients with relapsed or refractory systemic anaplastic large cell lymphoma compared with the pivotal study.

Abbreviations: CR, complete response; ORR, overall response rate; PFS, progression-free survival; SCT, stem cell transplantation (either autologous and/or allogeneic)..